<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">APROTININ</span><br/>(a-pro-ti'nin)<br/><span class="topboxtradename">Trasylol<br/></span><b>Classifications:</b> <span class="classification">blood formers, coagulators, and anticoagulants</span>; <span class="classification">hemostatic</span><br/><b>Prototype: </b>Aminocaproic acid<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10,000 KIU/mL injection (one KIU equals 0.14 mg)</p>
<h1><a name="action">Actions</a></h1>
<p>Polypeptide of bovine origin that inhibits protease. By interaction with certain proteases, aprotinin has antifibrinolytic
         effect, hemostatic stabilizing effect, and weak anticoagulant effect.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Aprotinin reduces postoperative bleeding in coronary bypass surgery patients by inhibiting fibrinolytic activity while preserving
         platelet adhesive function and prolonging postoperative bleeding time.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Prophylactically to reduce perioperative blood loss and need for blood transfusions during cardiopulmonary bypass in the course
         of repeat coronary artery bypass surgery. May also be used in selected cases of primary coronary artery bypass graft surgery
         where the risk of bleeding is especially high (i.e., impaired hemostasis, coagulopathy).
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to aprotinin and bovine products.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Patients with heparinized blood; patients previously treated with aprotinin; pregnancy (category B). Safety and efficacy in
         children are not established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Cardiac Surgery</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV Test Dose</span> 1-mL (10,000 kallikrein inactivator units [KIU]) given at least 10 min prior to loading dose (observe for signs of an allergic
               reaction) <span class="rdroute">IV Loading Dose</span> 2 million KIU over 2030 min after induction of anesthesia, but prior to sternotomy, add 2 million KIU to the priming
               fluid of the cardiopulmonary priming pump <span class="rdroute">IV Maintenance Dose</span> Constant infusion of 500,000 KIU/h, continue until the patient leaves the OR<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype"> IV Test Dose/Loading Dose:</span> Use as supplied (1 mL = 1.4 mg or 10,000 KIU) without further dilution.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">IV Test Dose:</span> Give direct IV push over 1 min.   <span class="methodtype">IV Loading Dose:</span>  Give over 2030 min.  <span class="methodtype">Continuous:</span> Follow with infusion at 50 mL/h. Use central venous catheter exclusively for aprotinin.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype"> Solution/additive:</span>
<span class="classification">amino acids</span>, <span class="classification">corticosteroids</span>, fat emulsion, <b>heparin,</b>
<span class="classification">tetracyclines</span>. 
               </p>
</td>
</tr>
</table>
<ul>
<li>Store at controlled room temperature.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Hypersensitivity reactions (rash, urticaria, <span class="speceff-life">anaphylaxis</span>). <span class="typehead">CV:</span> Tachycardia. <span class="typehead">Hematologic:</span> Thromboembolism. <span class="typehead">Skin:</span> Rash, urticaria. <span class="typehead">Urogenital:</span>
<span class="speceff-life">Nephrotoxicity</span> (elevated serum creatinine). <span class="typehead">Other:</span>
<span class="speceff-life">Bronchospasm</span>. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Heparin</b> results in further prolongation of the whole blood activated clotting time (ACT). 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Distribution:</span> Rapidly distributes into the extracellular fluid, then accumulates in proximal renal tubular epithelial cells; crosses placenta;
      distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized primarily in kidneys to small peptides or amino acids. <span class="typehead">Elimination:</span> Excreted by kidneys. <span class="typehead">Half-Life:</span> Initial 0.7 h, terminal 7 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor carefully for S&amp;S of hypersensitivity during administration (see Appendix F). If hypersensitivity occurs, immediately
            discontinue aprotinin and begin emergency treatment to prevent anaphylaxis.
         </li>
<li>Monitor cardiac status and pulmonary function carefully during infusion. Patients with a history of hypersensitivity to any
            allergens or who have previously received aprotinin are at special risk for hypersensitivity.
         </li>
<li>Lab tests: After surgery, monitor aPTT, ACT, and cardiac, pulmonary, renal, and liver functions.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>